Zymeworks Inc. announced the release of an abstract by ESMO with preliminary results from the company's Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate. Results from the study entitled “Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate (ADC) zanidatamab zovodotin (ZW49) in Solid Cancers” will be presented by Komal Jhaveri, MD, FACP, Medical Oncologist, Memorial Sloan Kettering Cancer Center in NYC, in a mini-oral presentation on September 12 at 5:25 pm CEST during the ESMO meeting being held September 9-13, 2022, at the Paris Expo Porte de Versailles in Paris, France. In an ongoing Phase 1 study of 76 patients with HER2+ cancers including gastric (28%) and breast (22%) cancers, preliminary results show that the majority of treatment related adverse events (TRAEs) were Grade 1 or 2 and included keratitis (42%), alopecia (25%) and diarrhea (21%).
https://www.marketscreener.com/quote/stock/ZYMEWORKS-INC-34658200/news/Zymeworks-Announces-Release-of-ESMO-Abstract-for-Phase-1-Study-of-Zanidatamab-Zovodotin-in-Solid-Can-41696630/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.